rct
    2010

    Oral Diindolylmethane (DIM): Pilot Evaluation of a Nonsurgical Treatment for Cervical Dysplasia

    Del Priore G, Gudipudi DK, Montemarano N, Restivo AM, Malanowska-Stega J, Arslan AA

    Published in Gynecologic Oncology

    Methodology

    Randomised placebo-controlled pilot trial of oral DIM (2 mg/kg/day) for 12 weeks in 64 women with biopsy-proven CIN 2 or 3.

    Key Findings

    Roughly half of participants improved on cytology, colposcopy or histology, but improvement rates did not differ significantly between DIM and placebo; treatment was well tolerated.

    Conclusions

    DIM was safe but showed no clear advantage over placebo for cervical dysplasia in this pilot.

    Limitations

    Underpowered pilot; high placebo regression rate; short follow-up.

    Supplements Studied

    DIM
    Compound

    Improvement rates did not differ significantly between DIM and placebo in CIN 2 or 3.

    Study Details

    Year:2010
    Sample Size:64
    Duration:12 weeks
    Quality Score:6/10

    Access Study

    View on DOIView on PubMedOriginal Source

    This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.